ANTI-CD20 THERAPY FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
Completed
- Conditions
- chronic graft-versus-host disease, allogeneic stem cell transplantation, B-cell depletion
- Registration Number
- NL-OMON27822
- Lead Sponsor
- niversity Medical Centre UtrechtP.O. Box 855003508 GA Utrecht, The Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1. Age > = 18 years
2. Chronic GVHD, including skin localization, refractory or dependent to first line treatment consisting of steroids and/or ciclosporine. Refractory cGVHD is defined as progressive cGVHD after at least 2 weeks of first line treatment or no response after 4 weeks of first line treatment.. Dependent cGVHD is defined as an inability to taper immunosuppressive treatment.
Exclusion Criteria
1. Relapse and a life expectancy of < 6 months
2. Life expectancy of < 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with a complete or partial response
- Secondary Outcome Measures
Name Time Method Proportion of patients with a complete response <br /><br>Proportion of patients with a partial response <br /><br>Proportion of patients with an immune-histochemical improvement in skin biopsies<br>Response duration <br /><br>Adverse events
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does anti-CD20 therapy modulate B-cell pathogenesis in chronic graft-versus-host disease post-allogeneic stem cell transplantation?
What is the comparative efficacy of anti-CD20 agents versus corticosteroids or rituximab in treating steroid-refractory chronic graft-versus-host disease?
Which biomarkers correlate with response to B-cell depletion in chronic graft-versus-host disease patients undergoing anti-CD20 therapy?
What are the long-term safety profiles of anti-CD20 monoclonal antibodies in immunocompromised cGVHD patients, including infusion-related toxicity management?
How do combination therapies involving anti-CD20 agents and JAK inhibitors compare to monotherapy in chronic graft-versus-host disease treatment strategies?